Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Free cash flow

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndFree cash flow (Million USD)YoY (%)
Dec 31, 2024468+25.47%
Dec 31, 2023373+58.64%
Dec 31, 2022235-21.04%
Dec 31, 2021298+462.76%
Dec 31, 202053-159.19%
Dec 31, 2019-89+65.17%
Dec 31, 2018-54-140.82%
Dec 31, 2017133-347.95%
Dec 31, 2016-54+35.69%
Dec 31, 2015-39-19.32%
Dec 31, 2014-49-5.33%
Dec 31, 2013-52-21.45%
Dec 31, 2012-66+86.88%
Dec 31, 2011-35

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat